Concordance between use of proton pump inhibitors and prescribing guidelines

Citation
Pi. Pillans et al., Concordance between use of proton pump inhibitors and prescribing guidelines, MED J AUST, 172(1), 2000, pp. 16-18
Citations number
18
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
MEDICAL JOURNAL OF AUSTRALIA
ISSN journal
0025729X → ACNP
Volume
172
Issue
1
Year of publication
2000
Pages
16 - 18
Database
ISI
SICI code
0025-729X(20000103)172:1<16:CBUOPP>2.0.ZU;2-5
Abstract
Objective: To determine (i) the relationship between prescriptions for prot on pump inhibitors (PPIs) and upper gastrointestinal conditions, and (ii) c ompliance with Pharmaceutical Benefits Scheme (PBS) prescribing guidelines for PPIs. Design: Drug utilisation evaluation. Setting: 800-bed metropolitan teaching hospital. Participants: 253 patients dispensed PPIs from the hospital pharmacy over f ive consecutive weeks (11 January to 15 February 1999). Main outcome measures: Recorded gastrointestinal conditions; previous trial of H-2- antagonist therapy; compliance with PBS criteria for prescribing P PIs. Results: Seventy patients (27.7%) had no appropriate upper gastrointestinal tract investigations, and 62 patients (24%) did not receive an adequate tr ial of H-2-antagonist therapy before the commencement of a PPI. The major i ndications for use of PPIs in investigated patients were gastro-oesophageal reflux in 99 (54%) and peptic ulcer disease in 30 (16.4%). In only 57 pati ents (22.5%) did PPI prescriptions comply with PBS prescribing guidelines. Clinical indications that failed to meet prescribing criteria included mild er forms of gastro-oesophageal reflux, gastritis/duodenitis, and non-specif ic dyspepsia with normal endoscopy results. Conclusion: Drug utilisation data indicate widespread use of PPIs outside c urrent prescribing guidelines. Many patients have not had relevant investig ations and/or an adequate trial of H-2-antagonist therapy. These findings e xplain the considerable hospital expenditure on PPIs.